Search results
Results from the WOW.Com Content Network
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
Shares of Regeneron were down over 2% in premarket trading. Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from ...
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...
Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
For premium support please call: 800-290-4726 more ways to reach us
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates. Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us